New vaccine developed for Chikungunya by French biotech Valneva

New York: New single dose chikungunya vaccine developed by French biotech Valneva is safe and produces an immune response, according to a phase 3 randomised controlled trial published in The Lancet.

After a single vaccination, VLA1553 induced antibody levels at a level that is



considered to protect against disease among 99 percent (263/266) of participants. There was no difference in immune response according to age.

While antibody levels declined 28 days after vaccination, seroprotection persisted in more than 96 per cent (233/242) participants after six months.